# US 2008/0076825 A1 · Novel Crystalline Forms of Entacapone and Production Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076825 A1
- Document ID: US20080076825A1
- Status: Published application
- Kind: A1
- Application number: 10/584,900
- Filed: 2004-12-27
- Published: 2008-03-27
- Earliest claimed: 2003-12-31
- Inventors: Thomas Bader; Markus Furegati; Oliver Jungmann
- Web page: https://patentgrep.com/patent/US20080076825A1

## CPC

- C07C 255/41: the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- A61P 25/16: Anti-Parkinson drugs
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to three novel forms of entacapone. These are peripheral and selective COMT inhibitors which in combination with levodopa and decarboxylase inhibitors can be used to treating Parkinson's syndrome. Said novel forms arise by crystallization of entacapone in respectively determined conditions. In certain cases, entacapone can be used as a raw product, in a special case it can be used in situ as the product of Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide. Also disclosed are improvements of said condensation in relation to the catalyst and the production of the two components thereof.

## Claims

### Claim 1

A crystalline form C of entacapone, characterized by the following XRD data:
Lattice spacing
Rel. intensity
Angle 2 theta (°)
d (Å)
I/Imax (%)
5.61
15.77
100
11.43
7.78
1
14.75
6.06
2
17.23
5.21
5
18.81
4.78
2
20.89
4.32
1
23.13
3.92
17
25.23
3.62
2
26.87
3.41
3
29.03
3.18
1
32.17
2.90
2

### Claim 2

A crystalline form D of entacapone, characterized by the following XRD data:
Lattice spacing
Rel. intensity
Angle 2 theta (°)
d (Å)
I/Imax (%)
6.84
12.95
99
11.84
7.51
6
12.12
7.34
7
13.52
6.59
49
14.8
6.04
23
15.56
5.75
40
16.54
5.42
31
16.9
5.30
22
17.98
4.99
37
18.84
4.77
12
19.06
4.72
13
20.72
4.36
18
21.44
4.22
28
22.24
4.07
12
23.4
3.88
22
24
3.79
39
24.62
3.70
76
25.34
3.60
51
26.5
3.46
65
27.44
3.35
100
28.08
3.28
51
29.24
3.16
15
29.98
3.09
17

### Claim 3

A crystalline form E of entacapone, characterized by the following XRD data:
Lattice spacing
Rel. intensity
Angle 2 theta (°)
d (Å)
I/Imax (%)
6.62
13.35
100
8.87
9.97
4
12.36
7.16
8
12.90
6.86
12
13.38
6.62
11
14.40
6.15
5
15.52
5.71
49
17.92
4.95
33
18.25
4.86
22
19.20
4.62
6
20.48
4.24
26
21.10
4.21
7
21.85
4.07
6
22.45
3.96
6
22.90
3.88
7
24.00
3.71
30
24.64
3.61
36
25.85
3.45
77
27.32
3.26
20

### Claim 4 (depends on 1)

A process for the preparation of the crystalline form C of entacapone as claimed in claim 1, characterized in that entacapone is crystallized from a mixture of at least one aromatic and at least one aliphatic hydrocarbon.

### Claim 5 (depends on 4)

The process as claimed in claim 4, characterized in that the aromatic hydrocarbon used is toluene and the aliphatic hydrocarbon used is n-heptane.

### Claim 6 (depends on 2)

A process for the preparation of the crystalline form D of entacapone as claimed in claim 2, characterized in that
a) entacapone is dissolved in a water-miscible solvent and this solution is added to water or a mixed aqueous system; or
b) entacapone is crystallized from a non-acidic solvent or a solvent mixture with at least one non-acidic component, in the presence of a strong acid.

### Claim 7 (depends on 6)

The process as claimed in claim 6, variant a), characterized in that it is carried out in THF/water, acetone/water, acetone/DMSO/water or n-propanol/water.

### Claim 8 (depends on 6)

The process as claimed in claim 6, variant b), characterized in that it is carried out in toluene/acetonitrile or toluene/acetonitrile/acetic acid.

### Claim 9 (depends on 6, 8)

The process as claimed in claim 6, variant b), or claim 8, characterized in that the acid used is hydrogen bromide.

### Claim 10 (depends on 3)

A process for the preparation of the crystalline form E of entacapone as claimed in claim 3, characterized in that entacapone is dissolved in a polar aprotic or alcoholic solvent and this solution is added to an aliphatic hydrocarbon immiscible with this solvent, in which entacapone is insoluble.

### Claim 11 (depends on 10)

The process as claimed in claim 10, characterized in that it is carried out in THF/n-hexane, THF/n-pentane, THF/cyclohexane or isopropanol/n-hexane.

### Claim 12 (depends on 6)

The process as claimed in claim 6, characterized in that crude entacapone is used.

### Claim 13 (depends on 8)

The process as claimed in claim 8, characterized in that entacapone is used in situ in the form of the product of a Knoevenagel condensation of 3,4-dihydroxy-5-nitrobenzaldehyde and 2-cyanoacetic acid diethylamide.

### Claim 14 (depends on 8)

The process as claimed in claim 8, characterized in that the acid used is hydrogen bromide and the process is carried out in toluene/acetonitrile/acetic acid.

### Claim 15 (depends on 1)

The crystalline form C, D or E of entacapone as claimed in claim 1, for use as a therapeutic active ingredient.

### Claim 16 (depends on 1)

A drug containing the crystalline form C, D or E of entacapone as claimed in claim 1, and a therapeutically inert excipient.

### Claim 17 (depends on 16)

The drug as claimed in claim 16 additionally containing levodopa and a decarboxylase inhibitor.

### Claim 18 (depends on 1)

The use of the crystalline form C, D or E of entacapone as claimed in claim 1, optionally in combination with levodopa and a decarboxylase inhibitor, for the treatment of Parkinson's disease or for the preparation of corresponding drugs.

### Claim 19

A process for the preparation of entacapone by a Knoevenagel condensation of 3,4-dihydroxy-5-nitrobenzaldehyde and N,N-diethyl-2-cyanoacetamide, characterized in that the catalyst used for this condensation is diethylamine/acetic acid.

### Claim 20 (depends on 19)

The process as claimed in claim 19, characterized in that the N,N-diethyl-2-cyanoacetamide used has been prepared by reacting cyanoacetic acid with diethylamine in the presence of dicyclohexylcarbodiimide.

### Claim 21 (depends on 19)

The process as claimed in claim 19, characterized in that the 3,4-dihydroxy-5-nitrobenzaldehyde used has been prepared by the demethylation of 5-nitrovanillin with AlCl3/pyridine in chlorobenzene.
